Carlsmed, Inc. (CARL) News
Track canonical SquawkNews coverage tagged to CARL, Carlsmed, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Carlsmed Price Target Maintained With a $23.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 01:44 PM UTC
L
BTIG reiterates Buy rating on Carlsmed, $23 price target
BTIG reiterated their Buy rating on Carlsmed's stock with a price target of $23.00.The price target implies an upside of 52.3% from the Sep 25 close of $15.10.Key takeaways from the analyst noteStrong Growth Trajectory:
EQUITY | Sep 28, 2026, 01:33 PM UTC
L
Carlsmed Names Richard Heppenstall as CFO
By Adriano MarcheseCarlsmed has appointed Richard Heppenstall as its new chief financial officer, effective immediately.Heppenstall brings a wealth of experience to the medical technology company, having served in financ
NEWS | Sep 28, 2026, 12:59 PM UTC
H
Carlsmed Affirms FY2026 Sales Guidance of $74.000M-$78.000M vs $74.830M Est
Carlsmed (NASDAQ: CARL ) affirms FY2026 sales outlook from $74.000 million-$78.000 million to $74.000 million-$78.000 million vs $74.830 million estimate.
LIVE | Sep 28, 2026, 12:37 PM UTC
H
Carlsmed Appoints Richard Heppenstall CFO, Succeeding Leo Greenstein; Co. Reiterates FY26 Revenue Range Of $74M - $78M
Carlsmed, Inc. (Nasdaq: CARL ) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Fin
LIVE | Sep 28, 2026, 12:32 PM UTC
H
Carlsmed, Inc. (CARL) Appoints New CFO, Reaffirms FY26 Revenue Outlook
Carlsmed appointed Richard Heppenstall as CFO, succeeding Leo Greenstein, and reaffirmed FY26 revenue guidance of $74—$78M.Material DetailsContext by AI AnalystThis is a management transition with steady guidance, reinfo
EARNINGS | Sep 28, 2026, 12:32 PM UTC
L
Carlsmed Appoints Richard Heppenstall as Chief Financial Officer
Company Reaffirms Fiscal Year 2026 GuidanceCARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. NASDAQ:CARL (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized sp
NEWS | Sep 28, 2026, 12:32 PM UTC
M
Carlsmed files patent infringement suit against DeGen Medical
Carlsmed filed a patent infringement lawsuit against DeGen Medical in U.S. District Court (SC), asserting eight patents and seeking injunctive relief and damages.
EQUITY | Sep 15, 2026, 11:03 PM UTC
L
Carlsmed names Jeffrey Bertolini chief operating officer
Carlsmed appointed Jeffrey Bertolini as chief operating officer, effective September 8, 2026, according to an 8-K filing.
REGULATION | Sep 08, 2026, 08:16 PM UTC
L
Carlsmed appoints new chief operating officer
Carlsmed, Inc. announced a chief operating officer appointment.
EQUITY | Sep 08, 2026, 08:06 PM UTC
L
Carlsmed Raises FY2026 Sales Guidance from $72.000M-$77.000M to $74.000M-$78.000M vs $74.830M Est
Carlsmed (NASDAQ: CARL ) raises FY2026 sales outlook from $72.000 million-$77.000 million to $74.000 million-$78.000 million vs $74.830 million estimate.
EARNINGS | Aug 05, 2026, 08:03 PM UTC
L
CARL - Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance
CARL - Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance
EARNINGS | Aug 05, 2026, 08:01 PM UTC
H
US CMS Finalizes Reimbursement for Carlsmed Aprevo
CMS sets favorable reimbursement for Carlsmed procedures
REGULATION | Aug 03, 2026, 12:13 PM UTC
H
CARL: Gets Favorable Reimbursement
CARL gets favorable reimbursement for aprevo lumbar procedures
EQUITY | Aug 03, 2026, 12:00 PM UTC
L
Needham Initiates Coverage On Carlsmed with Buy Rating, Announces Price Target of $17
Needham analyst David Saxon initiates coverage on Carlsmed (NASDAQ: CARL ) with a Buy rating and announces Price Target of $17.
EQUITY | Jul 01, 2026, 11:56 AM UTC